Breakthrough data on botensilimab/balstilimab in mss crc presented at the 2024 asco annual meeting

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the phase 1b trial of botensilimab in combination with balstilimab (bot/bal) in relapsed/refractory microsatellite stable colorectal cancer (r/r mss crc) with no active liver metastases (nlm) will be presented at the upcoming 2024 american society of clinical oncology (asco) annual meeting on june 1, 2024. the.
AGEN Ratings Summary
AGEN Quant Ranking